Cabozantinib in children with recurrent diffuse gliomas

Pediatr Blood Cancer. 2024 Sep;71(9):e31149. doi: 10.1002/pbc.31149. Epub 2024 Jun 17.

Authors

Ludmila Papusha¹, Margarita Zaytseva¹, Maria Senchenko¹, Agunda Sanakoeva¹, Agnesa Panferova¹, Tatiana Sharanda², Irina Vilesova¹, Alexandra Tarakanova¹, Ekaterina Salnikova¹, Natalia Usman¹, Anton Artemov¹, Alexander Karachunskiy¹, Alexey Maschan¹, Eugene Hwang^{3

4}, Roger J Packer^{4

5}, Galina Novichkova¹, Alexander Druy^{1

6}

Affiliations

¹ Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
² Amur Regional Children's Hospital, Blagoveshchensk, Russia.
³ Division of Oncology, Children's National Hospital, Washington, District of Columbia, USA.
⁴ Brain Tumor Institute, Children's National Hospital, Washington, District of Columbia, USA.
⁵ Center for Neuroscience and Behavioral Medicine, Washington, District of Columbia, USA.
⁶ Research Institute of Medical Cell Technologies, Yekaterinburg, Russia.

PMID: 38884269
DOI: 10.1002/pbc.31149

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Anilides* / therapeutic use
Antineoplastic Agents / therapeutic use
Brain Neoplasms* / drug therapy
Brain Neoplasms* / pathology
Child
Child, Preschool
Female
Glioma* / drug therapy
Glioma* / pathology
Humans
Male
Neoplasm Recurrence, Local* / drug therapy
Neoplasm Recurrence, Local* / pathology
Pyridines* / therapeutic use

Substances

cabozantinib
Pyridines
Anilides
Antineoplastic Agents

Grants and funding

Science for Children